Higher doses of radiotherapy cut treatment time by up to 75 per cent in localised prostate cancer patients, while maintaining high cure rates 29 Sep 2023 People with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. Find out more Show/Hide
ICR and Merck renew strategic alliance in discovery and development of innovative new small-molecule cancer drugs 22 Sep 2023 The Institute of Cancer Research, London, and science and technology company Merck have renewed their strategic alliance in the discovery and development of new cancer drugs. Find out more Show/Hide
ICR strategic commercial partner raises $226.5m in financing 18 Sep 2023 Apollo Therapeutics, a strategic partner of The Institute of Cancer Research, has raised more than $226m from investors to fund its ongoing collaboration with the ICR and other academic partners. Find out more Show/Hide
‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer 08 Sep 2023
Scan could guide use of drugs targeting tumours’ ‘scaffold’ to improve breast cancer treatment 06 Sep 2023
Researchers gain fascinating new insights into chromosome shortening – and identify new potential cancer drug targets 29 Aug 2023